This webinar is intended for outside of the US market only.
The recorded webinar will be available upon request by emailing [email protected]
During this webinar, Dr. Eduardo Lovo will present the rationale for using radiosurgery for patients with drug-refractory pain. He will focus on patient selection, the definition of the targets and structures at risk and the dose to be delivered. He will share his radiosurgery experience with the CyberKnife® System.
Dr. Eduardo Lovo, Neurosurgeon oncologist, Centro de Radiocirugía Robótica, San Jose, Costa Rica
Dr. Eduardo Lovo is the current Director of the International Cancer Center Group home to the one and only CyberKnife that operates in Central America. He is a neurosurgeon who introduced the second TomoTherapy® unit in Latin America and the first dedicated radiosurgery systems, leading the way to advanced SRS and SBRT in the region. The Cancer Center Group is focused on bringing improvements and innovation in radiation therapy solutions to its area of influence. Dr. Lovo´s current main interest is functional radiosurgery, particularly in pain and epilepsy, he is presently trying to demonstrate that radiomodulation can be achieved in a consistent manner and that radiation holds a future in refractory oncological pain. Dr. Lovo is an advocate of making SRS and advanced radiation therapy more widely accessible.
Moderated by: Prof. Scott G. Soltys, Co-Director of the Radiosurgery Program, Stanford University, California, USA
Dr. Soltys is a Professor in the department of Radiation Oncology at Stanford University. He serves as the co-director of the Stanford stereotactic radiosurgery program, the program director for the residency program, and is the senior editor for Central Nervous System submissions to the International Journal of Radiation Oncology Biology and Physics. He is the Radiation Oncology Chair on the NRG Oncology BN012 trial investigating pre-resection radiosurgery for brain metastases. His clinical and research interests focus on novel treatments of brain and spine tumors and functional disorders with stereotactic radiosurgery and radiotherapy.
